The company said it would work closely with the FDA to address the agency’s concerns, which the drugmaker expected to be communicated within the next 30 days. This is Sun Pharma’s second run-in with the FDA in less than two weeks.

Sun Pharmaceutical Industries Limited said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to an experimental drug for treating patchy baldness.